Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Wensel

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Pharmaceutical Research|March 23, 2011
Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical speciesYulia Vugmeyster, Pam Szklut, David Wensel, et al.
Journal of Virology|May 11, 2018
A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding AdnectinDavid Wensel, Yongnian Sun, Jonathan Davis, et al.
Antiviral Therapy|October 3, 2022
A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infectionMark Krystal, Shiven Chabria, Daren Austin, et al.
Antiviral Research|July 3, 2024
The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rateDavid Wensel, Margaret Gartland, Jagadish Beloor, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2017
Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV ActivityDavid Wensel, Yongnian Sun, Zhufang Li, et al.
Journal of Virology|August 4, 2019
GSK3732394: a Multi-specific Inhibitor of HIV EntryDavid Wensel, Yongnian Sun, Jonathan Davis, et al.
Journal of Molecular Biology|December 13, 2021
Novel Bent Conformation of CD4 Induced by HIV-1 Inhibitor Indirectly Prevents Productive Viral AttachmentDavid Wensel, Shawn Williams, David P Dixon, et al.
Molecular Pharmacology|June 25, 2017
A Functional Na<sub>V</sub>1.7-Na<sub>V</sub>Ab Chimera with a Reconstituted High-Affinity ProTx-II Binding SiteRamkumar Rajamani, Sophie Wu, Iyoncy Rodrigo, et al.
Viruses|October 26, 2024
Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937Brian McAuliffe, Paul Falk, Jie Chen, et al.
Rheumatology (Oxford, England)|January 25, 2011
Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeysCheryl Nickerson-Nutter, Lioudmila Tchistiakova, Nilufer P Seth, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Pharmaceutical Research|March 23, 2011
Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical speciesYulia Vugmeyster, Pam Szklut, David Wensel, et al.
Journal of Virology|May 11, 2018
A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding AdnectinDavid Wensel, Yongnian Sun, Jonathan Davis, et al.
Antiviral Therapy|October 3, 2022
A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infectionMark Krystal, Shiven Chabria, Daren Austin, et al.
Antiviral Research|July 3, 2024
The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rateDavid Wensel, Margaret Gartland, Jagadish Beloor, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2017
Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV ActivityDavid Wensel, Yongnian Sun, Zhufang Li, et al.
Journal of Virology|August 4, 2019
GSK3732394: a Multi-specific Inhibitor of HIV EntryDavid Wensel, Yongnian Sun, Jonathan Davis, et al.
Journal of Molecular Biology|December 13, 2021
Novel Bent Conformation of CD4 Induced by HIV-1 Inhibitor Indirectly Prevents Productive Viral AttachmentDavid Wensel, Shawn Williams, David P Dixon, et al.
Molecular Pharmacology|June 25, 2017
A Functional Na<sub>V</sub>1.7-Na<sub>V</sub>Ab Chimera with a Reconstituted High-Affinity ProTx-II Binding SiteRamkumar Rajamani, Sophie Wu, Iyoncy Rodrigo, et al.
Viruses|October 26, 2024
Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937Brian McAuliffe, Paul Falk, Jie Chen, et al.
Rheumatology (Oxford, England)|January 25, 2011
Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeysCheryl Nickerson-Nutter, Lioudmila Tchistiakova, Nilufer P Seth, et al.
Pageof 1